Sanofi Settlement With Lilly Paves The Way For Biosimilar Lantus
This article was originally published in The Pink Sheet Daily
Executive Summary
Eli Lilly’s copycat version of Sanofi’s blockbuster insulin Lantus could reach the market in the U.S. in December 2016 following a settlement agreement with Sanofi.